EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY 4.0

Post‐hoc safety/efficacy analyses from pediatric delgocitinib atopic dermatitis trials

Tatsuki Fukuie, Hiroyuki Toyama iD, Mai Tanaka, Katsuyo Ohashi-Doi, Kenji Kabashima

Pediatrics International · 2024

DOI: 10.1111/ped.15798 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Pediatrics International, 2024. Verfasst von Tatsuki Fukuie und 4 weiteren Autor:innen. Beteiligte Einrichtung: Allergy Center, National Center for Child Health and Development, Tokyo, Japan. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Ointments. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Tobacco Inc, Torii Pharmaceutical.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Delgocitinib ointment is usually recommended for use in children at a concentration of 0.25%. However, there are no clear criteria for dosing, except that a 0.5% formulation may also be used, depending on symptom severity. Treatment of atopic dermatitis is based on combinations of topical corticosteroids, tacrolimus ointment, and delgocitinib ointment, but there are no reports on the safety of delgocitinib ointment when used in combination with other drugs.

Methods

This is a post‐hoc analysis of data from two delgocitinib ointment trials with pediatric atopic dermatitis patients. The efficacy and safety of the 0.25% and 0.5% formulations were compared. Efficacy and safety were evaluated after up to 4 and 56 weeks of treatment, respectively. The safety of delgocitinib ointment when used in combination with topical corticosteroids and/or tacrolimus ointment was investigated.

Results

The dose–response relationship was examined according to baseline disease severity. The proportions of subjects with mild disease who achieved cumulative investigator's global assessment of 0 (clear) or 1 (almost clear) were 46.2% (0.25% ointment), 71.4% (0.5% ointment), and 7.7% (vehicle). For subjects with moderate to severe disease, the corresponding proportions were 19.0%, 20.0%, and 0.0%, respectively. No overall differences were seen in the safety profiles of the 0.25% and 0.5% delgocitinib ointment doses, or in the safety profiles of the two doses relating to disease severity or to concomitant use of topical corticosteroids and/or tacrolimus ointment.

Conclusions

These analyses indicate that after up to 4 weeks of treatment, delgocitinib 0.5% ointment may be more effective than the 0.25% dose for mild atopic dermatitis, and that after up to 56 weeks of treatment, delgocitinib is well tolerated in a pediatric trial population when used as prescribed in combination with topical corticosteroids and/or tacrolimus ointment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicOintmentsHumansChildMaleFemaleChild, PreschoolTreatment OutcomeDose-Response Relationship, DrugDouble-Blind MethodAdolescentQuinazolinonesTacrolimusPyrroles

Stichwörter der Autor:innen

JAK inhibitoratopic dermatitisdelgocitinibpediatric atopic dermatitissafety and efficacy

Substanzen

delgocitinibOintmentsQuinazolinonesTacrolimusPyrroles

Autor:innen und Institutionen

  • Allergy Center, National Center for Child Health and Development, Tokyo, Japan.
  • Medical Affairs Department, TORII Pharmaceutical Co Ltd, Tokyo, Japan.
  • Department of Dermatology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

ORCID-Profile: Hiroyuki Toyama

Förderung

  • Japan Tobacco Inc
  • Torii Pharmaceutical

Zitieren

APA

Fukuie, T., Toyama, H., Tanaka, M., Ohashi-Doi, K., & Kabashima, K. (2024). Post‐hoc safety/efficacy analyses from pediatric delgocitinib atopic dermatitis trials. Pediatrics International. https://doi.org/10.1111/ped.15798

Vancouver

Fukuie T, Toyama H, Tanaka M, Ohashi-Doi K, Kabashima K. Post‐hoc safety/efficacy analyses from pediatric delgocitinib atopic dermatitis trials. Pediatrics International. 2024. doi:10.1111/ped.15798

BibTeX
@article{Fukuie2024,
  author = {Fukuie, Tatsuki and Toyama, Hiroyuki and Tanaka, Mai and Ohashi-Doi, Katsuyo and Kabashima, Kenji},
  title = {Post‐hoc safety/efficacy analyses from pediatric delgocitinib atopic dermatitis trials},
  journal = {Pediatrics International},
  year = {2024},
  doi = {10.1111/ped.15798}
}
Kostenlos starten →